XM does not provide services to residents of the United States of America.

Philip Morris raises annual profit forecast on strong demand for nicotine pouches



<html xmlns="http://www.w3.org/1999/xhtml"><head><title>Philip Morris raises annual profit forecast on strong demand for nicotine pouches</title></head><body>

Oct 22 (Reuters) -Philip Morris International PM.N raised its annual profit forecast after beating third-quarter estimates on Tuesday, betting on higher prices and resilient demand for its heated tobacco products and ZYN nicotine pouches.

Growing consumer preference for smokeless alternatives to traditional combustible cigarettes and chewing tobacco products in the United States have supported demand for ZYN, which, according to the company, does not contain tobacco.

The Marlboro maker has been investing to expand production capacity for ZYN, in an effort to meet its strong demand.

U.S. ZYN shipments in the quarter grew 41.4% over the prior-year period, as supply-chain constraints started to ease.

The company's flagship heated tobacco device, IQOS, also saw strong growth in regions such as Japan, Europe and Indonesia.

Its consolidated shipment volumes for cigarettes rose 1.3% in the quarter, compared with a 0.4% rise in the preceding three months.

Shares of the company were up nearly 3% in premarket trading.

Philip Morris expects its 2024 adjusted earnings per share, excluding currency, to be between $6.85 and $6.91, compared with its prior range of $6.67 to $6.79.

It reported revenue of $9.91 billion for the third quarter, versus analysts' estimate of $9.69 billion, according to data compiled by LSEG.

Its quarterly adjusted profit of $1.91 per share also beat estimates of $1.82 per share.

Last week, Philip Morris said it, along with peers British American Tobacco BATS.L and Japan Tobacco 2914.T, would pay C$32.5 billion ($23.6 billion) to settle a long-running lawsuit in Canada.

A Quebec court awarded damages to about 100,000 smokers and ex-smokers who claimed these companies failed to adequately warn consumers about cancer risks.



Reporting by Anuja Bharat Mistry in Bengaluru; Editing by Shilpi Majumdar

</body></html>

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.